Drug Profile
Gram-negative infections therapeutic - TaiGen Biotechnology
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator TaiGen Biotechnology
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Gram-negative-infections in Taiwan
- 22 Nov 2017 Early research in Gram-negative infections in Taiwan (TaiGen Biotechnology pipeline, November 2017)